Opportunities in discovery and delivery of anticancer drugs targeting mitochondria and cancer cell metabolism

Advanced Drug Delivery Reviews

Volumn 61, Issue 14, 2009, Pages 1250-1275

  Pathania, Divya ^a   Millard, Melissa ^a   Neamati, Nouri ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Aerobic glycolysis; Biosynthetic alterations in cancer cells; Delocalized lipophilic cations; Glycolytic inhibitors; Inhibitors of mitochondrial electron transport chain; Mitochondrial apoptotic machinery; Mitochondrial redox system; Targeted drug delivery to cancer; Triphenylphosphonium compounds; Warburg effect

Indexed keywords

APOPTOTIC; CANCER CELLS; DELOCALIZED LIPOPHILIC CATIONS; MITOCHONDRIAL ELECTRON TRANSPORT CHAIN; REDOX SYSTEMS; TARGETED DRUG DELIVERY;

BIOCHEMISTRY; BIOSYNTHESIS; CELL DEATH; DNA; DRUG DELIVERY; ELECTRON TRANSITIONS; ELECTRON TRANSPORT PROPERTIES; ENZYMES; MACHINERY; MITOCHONDRIA; NUCLEIC ACIDS; PATHOLOGY; PHOSPHORYLATION; PLANTS (BOTANY); POSITIVE IONS; TUMORS;

METABOLISM;

1 ETHYL 2 [[3 ETHYL 5 (3 METHYLBENZOTHIAZOLIN 2 YLIDENE) 4 OXOTHIAZOLIDIN 2 YLIDENE]METHYL]PYRIDINIUM CHLORIDE; ACETOGENIN; ALPHA TOCOPHEROL SUCCINATE; AMINOLEVULINIC ACID; ANTINEOPLASTIC AGENT; AZD 7545; BENZYL ISOTHIOCYANATE; CAP 232; DEOXYGLUCOSE; DICHLOROACETIC ACID; DIPHENYLIODONIUM SALT; DITERCALINIUM; FLUTAMIDE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; JASMONIC ACID METHYL ESTER; KONINGIC ACID; LONIDAMINE; PHOSPHOGLYCERATE KINASE; PHOSPHOGLYCERATE MUTASE; PHOTOFRIN; RADICICOL; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE); RHEIN; RHODAMINE 123; ROTENONE; STIGMATELLIN; SUCCINATE DEHYDROGENASE; TETRAPHENYLPHOSPHONIUM; TH 070; TLN 232; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BIOENERGY; BRAIN CANCER; BREAST CANCER; CANCER CELL; CANCER INVASION; CANCER THERAPY; CELL METABOLISM; CELL PROLIFERATION; CITRIC ACID CYCLE; CLINICAL TRIAL; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG ERUPTION; DRUG STRUCTURE; DRUG TARGETING; ENERGY YIELD; ENZYME ACTIVITY; FATTY ACID SYNTHESIS; GENE MUTATION; GLYCOLYSIS; HEAD AND NECK TUMOR; HEPATITIS; HUMAN; HYPERTENSION; KIDNEY CARCINOMA; MELANOMA; MEMBRANE PERMEABILITY; METASTASIS; MITOCHONDRIAL ENERGY TRANSFER; MITOCHONDRIAL RESPIRATION; MITOCHONDRION; MULTIPLE CYCLE TREATMENT; NEPHROTOXICITY; NONHUMAN; OXIDATION REDUCTION STATE; OXIDATIVE PHOSPHORYLATION; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROTEIN ANALYSIS; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN SYNTHESIS; PROTON MOTIVE FORCE; RECURRENT CANCER; RESPIRATION CONTROL; REVIEW; SOLID TUMOR; STRUCTURE ACTIVITY RELATION; VOMITING;

ANTINEOPLASTIC AGENTS; APOPTOSIS REGULATORY PROTEINS; CITRIC ACID CYCLE; DRUG DELIVERY SYSTEMS; DRUG DISCOVERY; ENERGY METABOLISM; GLYCOLYSIS; HUMANS; MITOCHONDRIA; MODELS, BIOLOGICAL; NEOPLASMS; OXIDATION-REDUCTION;

EID: 71549171732     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.addr.2009.05.010     Document Type: Review

References (339)

1. Alberts B., Johnson A., Lewis J., Raff M., Roberts K., and Walter P. Molecular biology of the cell. Garland Science. fifth ed. (2008), Taylor and Francis Group, New York
2. Wang X. The expanding role of mitochondria in apoptosis. Genes Dev. 15 (2001) 2922-2933
3. Babcock D.F., Herrington J., Goodwin P.C., Park Y.B., and Hille B. Mitochondrial participation in the intracellular Ca2+ network. J. Cell Biol. 136 (1997) 833-844
4. Gutterman D.D. Mitochondria and reactive oxygen species: an evolution in function. Circ. Res. 97 (2005) 302-304
5. Wallace D.C. A mitochondrial paradigm of metabolic and degenerative diseases, aging, and cancer: a dawn for evolutionary medicine. Annu. Rev. Genet. 39 (2005) 359-407
6. Chan D.C. Mitochondria: dynamic organelles in disease, aging, and development. Cell 125 (2006) 1241-1252
7. Højlund K., Mogensen M., Sahlin K., and Beck-Nielsen H. Mitochondrial dysfunction in type 2 diabetes and obesity. Endocrinol. Metab. Clin. North Am. 37 (2008) 713-731
8. Warburg O. On the origin of cancer cells. Science 123 (1956) 309-314
9. Bui T., and Thompson C.B. Cancer's sweet tooth. Cancer Cells 9 (2006) 419-420
10. Kim J.W., and Dang C.V. Cancer's molecular sweet tooth and the Warburg effect. Cancer Res. 66 (2006) 892-8930
11. DeBerardinis J.R., Lum J.J., Hatzivassiliou G., and Thompson C. The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab. 7 (2008) 11-20
12. Gatenby R.A., Gawlinski E.T., Gmitro A.F., Kaylor B., and Gillies R. Acid-mediated tumor invasion: a multidisciplinary study. Cancer Cell Res. 66 (2006) 5216-5223
13. Kim J., and Dang C.V. Multifaceted roles of glycolytic enzymes. Trends Biochem. Sci. 30 (2005) 142-150
14. Fantin V.R., St-Pierre J., and Leder P. Attenuation of LDH-A expression uncovers a link between glycolysis, mitochondrial physiology, and tumor maintenance. Cancer Cells 9 (2006) 425-434
15. Carew J.S., and Huang P. Mitochondrial defects in cancer. Mol. Cancer. (2002) 1
16. Alternberg B., and Greulich K.O. Genes of glycolysis are ubiquitously overexpressed in 24 cancer classes. Genomics 84 (2004) 1014-1020
17. Langbein S., Zerilli M., ZurHausen A., Staiger W., Rensch-Boschert K., Lukan N., Popa J., Ternullo M.P., Steidler A., Weiss C., Grobholz R., Willeke F., Alken P., Stassi G., Schubert P., and Coy J.F. Expression of transketolase TKTL1 predicts colon and urothelial cancer patient survival: Warburg effect reinterpreted. Br. J. Cancer 94 (2006) 578-585
18. Selak M.A., Armour S.M., MacKenzie E.D., Boulahbel H., Watson D.G., Mansfield K.D., Pan Y., Simon M.C., Thompson C.B., Gottlieb E., and Succinate links T.C.A. cycle dysfunction to oncogenesis by inhibiting HIF-alpha prolyl hydroxylase. Cancer Cells 7 (2005) 77-85
19. Harris A.L. Hypoxia-a key regulatory factor in tumour growth. Nat. Rev., Cancer 2 (2002) 38-47
20. Kim J.W., Gardner L.B., and Dang C.V. Oncogenic alterations of metabolism and the Warburg effect. Drug Discov. Today Dis. Mech. 2 (2005) 233-238
21. Hatzivassiliou G., Andreadis C., and Thompson C.B. Akt-directed metabolic alterations in cancer. Drug Discov. Today Dis. Mech. 2 (2005) 255-262
22. Samudi I., Fiegl M., and Andreeff M. Mitochondrial uncoupling and the Warburg effect: molecular basis for the reprogramming of cancer cell metabolism. Cancer Res. 69 (2009) 2163-2166
23. Mathupala S.P., Ko Y.H., and Pedersen P.L. Hexokinase II: cancer's double-edged sword acting as both facilitator and gatekeeper of malignancy when bound to mitochondria. Oncogene 25 (2006) 4777-4781
24. Robey R.B., and Hay N. Mitochondrial hexokinases, novel mediators of the antiapoptotic effects of growth factors and Akt. Oncogene 25 (2006) 4683-4696
25. Lynch R.M., Fogarty K.E., and Fay F.S. Modulation of hexokinase association with mitochondria analyzed with quantitative three-dimensional confocal microscopy. J. Cell Biol. 112 (1991) 385-395
26. Kang H.T., and Hwang E.S. 2-Deoxyglucose: an anticancer and antiviral therapeutic, but not any more a low glucose mimetic. Life Sci. 78 (2006) 1392-1399
27. Maschek G., Savaraj N., Priebe W., Braunschweiger P., Hamilton K., Tidmarsh G.F., De-Young L.R., and Lampidis T.J. 2-deoxy-D-glucose increases the efficacy of adriamycin and paclitaxel in human osteosarcoma and non-small cell lung cancers in vivo. Cancer Res. 64 (2004) 31-34
28. Egler V., Korur S., Failly M., Boulay J.L., Imber R., Lino M.M., and Merlo A. Histone deacetylase inhibition and blockade of the glycolytic pathway synergistically induce glioblastoma cell death. Clin. Cancer Res. 14 (2008) 3132-3140
29. Threshold Pharmaceuticals. Product Pipeline, 2-Deoxyglucose (2009)
30. Board M., Colquhoun A., and Newsholme E.A. High Km glucose-phosphorylating (glucokinase) activities in a range of tumor cell lines and inhibition of rates of tumor growth by the specific enzyme inhibitor mannoheptulose. Cancer Res. 55 (1995) 3278-3285
31. Gottlob K., Majewski N., Kennedy S., Kandel E., Robey R.B., and Hay N. Inhibition of early apoptotic events by Akt/PKB is dependent on the first committed step of glycolysis and mitochondrial hexokinase. Genes Dev. 15 (2001) 1406-1418
32. Pelicano H., Martin D.S., Xu R.H., and Huang P. Glycolysis inhibition for anticancer treatment. Oncogene 25 (2006) 4633-4646
33. Xu R.H., Pelicano H., Zhang H., Giles F.J., Keating M.J., and Huang P. Synergistic effect of targeting mTOR by rapamycin and depleting ATP by inhibition of glycolysis in lymphoma and leukemia cells. Leukemia 19 (2005) 2153-2158
34. Floridi A., Paggi M.G., Marcante M.L., Silvestrini B., Caputo A., and DeMartino C. Lonidamine, a selective inhibitor of aerobic glycolysis of murine tumor cells. J. Natl. Cancer Inst. 66 (1981) 497-499
35. Floridi A., Bruno T., Miccadei S., Fanciulli M., Federico A., and Paggi M.G. Enhancement of doxorubicin content by the antitumor drug lonidamine in resistant Ehrlich ascites tumor cells through modulation of energy metabolism. Biochem. Pharmacol. 56 (1998) 841-849
36. Rosbe K.W., Brann T.W., Holden S.A., Teicher B.A., and Frei III E. Effect of lonidamine on the cytotoxicity of four alkylating agents in vitro. Cancer Chemother. Pharmacol. 25 (1989) 32-36
37. Martindale: the complete drug reference. thirty fifth ed. (2005), Pharmaceutical Press, London
38. U.S. National Institutes of Health. Clinical trials. gov, Lonidamine (2009)
39. Goldin N., Arzoine L., Heyfets A., Israelson A., Zaslavsky Z., Bravman T., Bronner V., Notcovich A., Shoshan-Barmatz V., and Flescher E. Methyl jasmonates binds to and detaches mitochondria-bound hexokinase. Oncogene 27 (2008) 4636-4643
40. Shih W.L., Liao M.H., Yu F.L., Lin P.Y., Hsu H.Y., and Chiu S.J. AMF/PGI transactivates the MMP-3 gene through the activation of Src-RhoA-phosphatidylinositol 3-kinase signaling to induce hepatoma cell migration. Cancer Lett. 270 (2008) 202-217
41. Scatena R., Bottoni P., Pontoglio A., Mastrototaro L., and Giardina B. Glycolytic enzyme inhibitors in cancer treatment. Expert Opin. Investig. Drugs 17 (2008) 1533-1545
42. Chesney J., Mitchell R., Benigni F., Bacher M., Spiegel L., Al-Abed Y., Han J.H., Metz C., and Bucala R. An inducible gene product for 6-phosphofructo-2-kinase with an AU-rich instability element: role in tumor cell glycolysis and the Warburg effect. Proc. Natl. Acad. Sci. U. S. A. 96 (1999) 3047-3052
43. Tong X., Zhao F., and Thompson C.B. The molecular determinants of de novo nucleotide biosynthesis in cancer cells. Curr. Opin. Genet. Dev. 19 (2009) 32-37
44. Clem B., Telang S., Clem A., Yalcin A., Meier J., Simmons A., Rasku M.A., Arumugam S., Dean W.L., Eaton J., Lane A., Trent J.O., and Chesney J. Small-molecule inhibition of 6-phosphofructo-2-kinase activity suppresses glycolytic flux and tumor growth. Mol. Cancer Ther. 7 (2008) 110-120
45. Jones A.R., and Cooper T.G. Metabolism of 36Cl-ornidazole after oral application to the male rat in relation to its antifertility activity. Xenobiotica 27 (1997) 711-721
46. Moreno-Sánchez R., Rodríguez-Enríquez S., Marín-Hernández A., and Saavedra E. Energy metabolism in tumor cells. FEBS J. 274 (2007) 1393-1418
47. Nakazawa M., Uehara T., and Nomura Y. Koningic acid (a potent glyceraldehyde-3-phosphate dehydrogenase inhibitor)-induced fragmentation and condensation of DNA in NG108-15 cells. J. Neurochem. 68 (1997) 2493-2499
48. Lay A.J., Jiang X.M., Kisker O., Flynn E., Underwood A., Condron R., and Hogg P.J. Phosphoglycerate kinase acts in tumour angiogenesis as a disulphide reductase. Nature 408 (2000) 869-873
49. Evans M.J., Saghatelian A., Sorensen E.J., and Cravatt B.F. Target discovery in small-molecule cell-based screens by in situ proteome reactivity profiling. Nat. Biotechnol. 23 (2005) 1303-1307
50. García-Alles L.F., and Erni B. Synthesis of phosphoenol pyruvate (PEP) analogues as inhibitors of PEP-utilizing enzymes. Eur. J. Biochem. 269 (2002) 3226-3236
51. Thallion Pharmaceuticals. Drug Development, TLN-232 (2009)
52. Raïs C.B., Puigjaner J., Brandes J.L., Creppy E., Saboureau D., Ennamany R., Lee W.N., Boros L.G., and Cascante M. Oxythiamine and dehydroepiandrosterone induce a G1 phase cycle arrest in Ehrlich's tumor cells through inhibition of the pentose cycle. FEBS Lett. 456 (1999) 113-118
53. Carmeliet P., Dor Y., Herbert J.M., Fukumura D., Brusselmans K., Dewerchin M., Neeman M., Bono F., Abramovitch R., Maxwell P., Koch C.J., Ratcliffe P., Moons L., Jain R.K., Collen D., and Keshert E. Role of HIF-1alpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature 394 (1998) 485-490
54. Semenza G.L., Roth P.H., Fang H.M., and Wang G.L. Transcriptional regulation of genes encoding glycolytic enzymes by hypoxia-inducible factor 1. J. Biol. Chem. 269 (1994) 23757-23763
55. 2 tension. Proc. Natl. Acad. Sci. U. S. A. 92 (1995) 5510-5514
56. Tian H., McKnight S.L., Russell D.W., and Endothelial P.A.S. Domain protein 1 (EPAS1), a transcription factor selectively expressed in endothelial cells. Genes Dev. 11 (1997) 72-82
57. Brusselmans K., Bono F., Maxwell P., Dor Y., Dewerchin M., Collen D., Herbert J.M., and Carmeliet P. Hypoxia-inducible factor-2alpha (HIF-2alpha) is involved in the apoptotic response to hypoglycemia but not to hypoxia. J. Biol. Chem. 276 (2001) 39192-39196
58. Makino Y., Kanopka A., Wilson W.J., Tanaka H., and Poellinger L. Inhibitory PAS domain protein (IPAS) is a hypoxia-inducible splicing variant of the hypoxia-inducible factor-3alpha locus. J. Biol. Chem. 277 (2002) 32405-32408
59. Fukuda R., Hirota K., Fan F., Jung Y.D., Ellis L.M., and Semenza G.L. Insulin-like growth factor 1 induces hypoxia-inducible factor 1-mediated vascular endothelial growth factor expression, which is dependent on MAP kinase and phosphatidylinositol 3-kinase signaling in colon cancer cells. J. Biol. Chem. 277 (2002) 38205-38211
60. 2 sensing. Science 292 (2001) 464-468
61. Jeong J.W., Bae M.K., Ahn M.Y., Kim S.H., Sohn T.K., Bae M.H., Yoo M.A., Song E.J., Lee K.J., and Kim K.W. Regulation and destabilization of HIF-1alpha by ARD1-mediated acetylation. Cell 111 (2002) 709-720
62. Mahon P.C., Hirota K., and Semenza G.L. FIH-1: a novel protein that interacts with HIF-1alpha and VHL to mediate repression of HIF-1 transcriptional activity. Genes Dev. 15 (2001) 2675-2686
63. Semenza G.L. Evaluation of HIF-1 inhibitors as anticancer agents. Drug Discov. Today 12 (2007) 853-859
64. Miyazaki T., Neff L., Tanaka S., Horne W., and Baron R. Regulation of cytochrome c oxidase activity by c-Src in osteoclasts. J. Cell Biol. 160 (2003) 709-718
65. Hüttemann M., Lee I., Samavati L., Yu H., and Doan J. Regulation of mitochondrial oxidative phosphorylation through cell signaling. Biochim. Biophys. Acta 1773 (2007) 1701-1720
66. Boerner J., Demory M., Silva C., and Parsons S. Phosphorylation of Y845 on the epidermal growth factor receptor mediates binding to the mitochondrial protein cytochrome c oxidase subunit II. Mol. Cell. Biol. 24 (2004) 7059-7071
67. Fan M., Rhee J., St-Pierre J., Handschin C., Puigserver P., Lin J., Jäeger S., Erdjument-Bromage H., Tempst P., and Spiegelman B. Suppression of mitochondrial respiration through recruitment of p160 myb binding protein to PGC-1alpha: modulation by p38 MAPK. Genes Dev. 18 (2004) 278-289
68. Miyamoto S., Murphy A., and Brown J. Akt mediated mitochondrial protection in the heart: metabolic and survival pathways to the rescue. J. Bioenerg. Biomembr. 41 (2009) 169-180
69. Roberts P., and Der C. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene 26 (2007) 3291-3310
70. Cheng J., Lindsley C., Cheng G., Yang H., and Nicosia S. The Akt/PKB pathway: molecular target for cancer drug discovery. Oncogene 24 (2005) 7482-7492
71. Turrens J. Mitochondrial formation of reactive oxygen species. J. Physiol. 552 (2003) 335-344
72. Bell E., and Chandel N. Mitochondrial oxygen sensing: regulation of hypoxia-inducible factor by mitochondrial generated reactive oxygen species. Essays Biochem. 43 (2007) 17-27
73. Goetz M., and Luch A. Reactive species: a cell damaging rout assisting to chemical carcinogens. Cancer Lett. 266 (2008) 73-83
74. Lau A., Wang Y., and Chiu J. Reactive oxygen species: current knowledge and applications in cancer research and therapeutic. J. Cell Biochem. 104 (2008) 657-667
75. Morriss G., and New D. Effect of oxygen concentration on morphogenesis of cranial neural folds and neural crest in cultured rat embryos. J. Embryol. Exp. Morphol. 54 (1979) 17-35
76. Genbacev O., Zhou Y., Ludlow J., and Fisher S. Regulation of human placental development by oxygen tension. Science 277 (1997) 1669-1672
77. Kang S., Park J., and Cha S. Multipotent, dedifferentiated cancer stem-like cells from brain gliomas. Stem Cells Dev. 15 (2006) 423-435
78. Helczynska K., Kronblad A., Jögi A., Nilsson E., Beckman S., Landberg G., and Påhlman S. Hypoxia promotes a dedifferentiated phenotype in ductal breast carcinoma in situ. Cancer Res. 63 (2003) 1441-1444
79. Holmquist L., Löfstedt T., and Påhlman S. Effect of hypoxia on the tumor phenotype: the neuroblastoma and breast cancer models. Adv. Exp. Med. Biol. 587 (2006) 179-193
80. Jögi A., Øra I., Nilsson H., Lindeheim A., Makino Y., Poellinger L., Axelson H., and Påhlman S. Hypoxia alters gene expression in human neuroblastoma cells toward an immature and neural crest-like phenotype. Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 7021-7026
81. Gustafsson M., Zheng X., Pereira T., Gradin K., Jin S., Lundkvist J., Ruas J., Poellinger L., Lendahl U., and Bondesson M. Hypoxia requires notch signaling to maintain the undifferentiated cell state. Dev. Cell. 9 (2005) 617-628
82. Bourges I., Mucchielli M., Herbert C., Guiard B., Dujardin G., and Meunier B. Multiple defects in the respiratory chain lead to the repression of genes encoding components of the respiratory chain and TCA cycle enzymes. J. Mol. Biol. 387 (2009) 1081-1091
83. Janssen R., Nijtmans L., van den Heuvel L., and Smeitink J. Mitochondrial complex I: structure, function and pathology. J. Inherit. Metab. Dis. 29 (2006) 499-515
84. Koopman W., Verkaart S., Visch H., van Emst-de Vries S., Nijtmans L., Smeitink J., and Willems P. Human NADH:ubiquinone oxidoreductase deficiency: radical changes in mitochondrial morphology?. Am. J. Physiol., Cell Physiol. 293 (2007) C22-29
85. 2-. -mediated mitochondrial outgrowth. Am. J. Physiol., Cell Physiol. 288 (2005) C1440-1450
86. Wallace K., and Starkov A. Mitochondrial targets of drug toxicity. Annu. Rev. Pharmacol. Toxicol. 40 (2000) 353-388
87. Degli Esposti M., Crimi M., and Ghelli A. Natural variation in the potency and binding sites of mitochondrial quinone-like inhibitors. Biochem. Soc. Trans. 22 (1994) 209-213
88. Fato R., Bergamini C., Bortolus M., Maniero A.L., Leoni S., Ohnishi T., and Lenaz G. Differential effects of mitochondrial Complex I inhibitors on production of reactive oxygen species. Biochim. Biophys. Acta. 1787 (2009) 384-392
89. Okun J., Lümmen P., and Brandt U. Three classes of inhibitors share a common binding domain in mitochondrial complex I (NADH:ubiquinone oxidoreductase). J. Biol. Chem. 274 (1999) 2625-2630
90. Royo I., DePedro N., Estornell E., Cortes D., Peláez F., and Tormo J. In vitro antitumor SAR of threo/cis/threo/cis/erythro bis-THF acetogenins: correlations with their inhibition of mitochondrial Complex I. Oncol. Res. 13 (2003) 521-528
91. Chapuis J., Khdour O., Cai X., Lu J., and Hecht S. Synthesis and characterization of Deltalac-acetogenins that potently inhibit mitochondrial complex I. Bioorg. Med. Chem. 17 (2009) 2204-2209
92. Majander A., Finel M., and Wikström M. Diphenyleneiodonium inhibits reduction of iron-sulfur clusters in the mitochondrial NADH-ubiquinone oxidoreductase (Complex I). J. Biol. Chem. 269 (1994) 21037-21042
93. Kean E., Gutman M., and Singer T. Studies on the respiratory chain-linked nicotinamide adenine dinucleotide dehydrogenase. XXII. Rhein, a competitive inhibitor of the dehydrogenase. J. Biol. Chem. 246 (1971) 2346-2353
94. Li N., Ragheb K., Lawler G., Sturgis J., Rajwa B., Melendez J., and Robinson J. DPI induces mitochondrial superoxide-mediated apoptosis. Free Radic. Biol. Med. 34 (2003) 465-477
95. Friedrich T., Ohnishi T., Forche E., Kunze B., Jansen R., Trowitzsch W., Höfle G., Reichenbach H., and Weiss H. Two binding sites for naturally occurring inhibitors in mitochondrial and bacterial NADH:ubiquinone oxidoreductase (complex I). Biochem. Soc. Trans. 22 (1994) 226-230
96. Miyoshi H., Inoue M., Okamoto S., Ohshima M., Sakamoto K., and Iwamura H. Probing the ubiquinone reduction site of mitochondrial complex I using novel cationic inhibitors. J. Biol. Chem. 272 (1997) 16176-16183
97. Miyoshi H., Iwata J., Sakamoto K., Furukawa H., Takada M., Iwamura H., Watanabe T., and Kodama Y. Specificity of pyridinium inhibitors of the ubiquinone reduction sites in mitochondrial complex I. J. Biol. Chem. 273 (1998) 17368-17374
98. Glover C., Rabow A., Isgor Y., Shoemaker R., and Covell D. Data mining of NCI's anticancer screening database reveals mitochondrial complex I inhibitors cytotoxic to leukemia cell lines. Biochem. Pharmacol. 73 (2007) 331-340
99. Monti E., Supino R., Colleoni M., Costa B., Ravizza R., and Gariboldi M. Nitroxide TEMPOL impairs mitochondrial function and induces apoptosis in HL60 cells. J. Cell Biochem. 82 (2001) 271-276
100. Trnka J., Blaikie F., Smith R., and Murphy M. A mitochondria-targeted nitroxide is reduced to its hydroxylamine by ubiquinol in mitochondria. Free Radic. Biol. Med. 44 (2008) 1406-1419
101. Eng C., Kiuru M., Fernandez M., and Aaltonen L. A role for mitochondrial enzymes in inherited neoplasia and beyond. Nat. Rev., Cancer 3 (2003) 193-202
102. Schilling B., Murray J., Yoo C., Row R., Cusack M., Capaldi R., and Gibson B. Proteomic analysis of succinate dehydrogenase and ubiquinol-cytochrome c reductase (Complex II and III) isolated by immunoprecipitation from bovine and mouse heart mitochondria. Biochim. Biophys. Acta 1762 (2006) 213-222
103. Gimenez-Roqueplo A., Favier J., Rustin P., Mourad J., Plouin P., Corvol P., Rötig A., and Jeunemaitre X. The R22X mutation of the SDHD gene in hereditary paraganglioma abolishes the enzymatic activity of complex II in the mitochondrial respiratory chain and activates the hypoxia pathway. Am. J. Hum. Genet. 69 (2001) 1186-1197
104. King A., Selak M., and Gottlieb E. Succinate dehydrogenase and fumarate hydratase: linking mitochondrial dysfunction and cancer. Oncogene 25 (2006) 4675-4682
105. Byun H., Kim H., Lim J., Seo Y., and Yoon G. Mitochondrial dysfunction by complex II inhibition delays overall cell cycle progression via reactive oxygen species production. J. Cell Biochem. 104 (2008) 1747-1759
106. Gomez-Lazaro M., Galindo M., Melero-Fernandez de Mera R., Fernandez-Gómez F., Concannon C., Segura M., Comella J., Prehn J., and Jordan J. Reactive oxygen species and p38 mitogen-activated protein kinase activate Bax to induce mitochondrial cytochrome c release and apoptosis in response to malonate. Mol. Pharmacol. 71 (2007) 736-743
107. Dong L., Low P., Dyason J., Wang X., Prochazka L., Witting P., Freeman R., Swettenham E., Valis K., Liu J., Zobalova R., Turanek J., Spitz D., Domann F., Scheffler I., Ralph S., and Neuzil J. Alpha-tocopheryl succinate induces apoptosis by targeting ubiquinone-binding sites in mitochondrial respiratory complex II. Oncogene 27 (2008) 4324-4335
108. Neuzil J., Dyason J., Freeman R., Dong L., Prochazka L., Wang X., Scheffler I., and Ralph S. Mitocans as anti-cancer agents targeting mitochondria: lessons from studies with vitamin E analogues, inhibitors of complex II. J. Bioenerg. Biomembranes 39 (2007) 65-72
109. Kelso G., Porteous C., Coulter C., Hughes G., Porteous W., Ledgerwood E., Smith R., and Murphy M. Selective targeting of a redox-active ubiquinone to mitochondria within cells: antioxidant and antiapoptotic properties. J. Biol. Chem. 276 (2001) 4588-4596
110. Guzy R., Hoyos B., Robin E., Chen H., Liu L., Mansfield K., Simon M., Hammerling U., and Schumacker P. Mitochondrial complex III is required for hypoxia-induced ROS production and cellular oxygen sensing. Cell Metab. 1 (2005) 401-408
111. Armstrong J., Yang H., Duan W., and Whiteman M. Cytochrome bc(1) regulates the mitochondrial permeability transition by two distinct pathways. J. Biol. Chem. 279 (2004) 50420-50428
112. von Jagow G., and Link T. Use of specific inhibitors on the mitochondrial bc1 complex. Methods Enzymol. 126 (1986) 253-271
113. Gurung B., Yu L., and Yu C. Stigmatellin induces reduction of iron-sulfur protein in the oxidized cytochrome bc1 complex. J. Biol. Chem. 283 (2008) 28087-28094
114. Xiao D., Powolny A., and Singh S. Benzyl isothiocyanate targets mitochondrial respiratory chain to trigger reactive oxygen species-dependent apoptosis in human breast cancer cells. J. Biol. Chem. 283 (2008) 30151-30163
115. Cooper C., and Brown G. The inhibition of mitochondrial cytochrome oxidase by the gases carbon monoxide, nitric oxide, hydrogen cyanide and hydrogen sulfide: chemical mechanism and physiological significance. J. Bioenerg. Biomembranes 40 (2008) 533-539
116. Shaban H., Gazzotti P., and Richter C. Cytochrome c oxidase inhibition by N-retinyl-N-retinylidene ethanolamine, a compound suspected to cause age-related macula degeneration. Arch. Biochem. Biophys. 394 (2001) 111-116
117. Dupont J., Schwaller M., and Dodin G. Ditercalinium, a nucleic acid binder, inhibits the respiratory chain of isolated mammalian mitochondria. Cancer Res. 50 (1990) 7966-7972
118. Capuano F., Guerrieri F., and Papa S. Oxidative phosphorylation enzymes in normal and neoplastic cell growth. J. Bioenerg. Biomembranes 29 (1997) 379-384
119. Espineda C., Chang J., Twiss J., Rajasekaran S., and Rajasekaran A. Repression of Na,K-ATPase beta1-subunit by the transcription factor snail in carcinoma. Mol. Biol. Cell 15 (2004) 1364-1373
120. Isidoro A., Martínez M., Fernández P., Ortega A., Santamaría G., Chamorro M., Reed J., and Cuezva J. Alteration of the bioenergetic phenotype of mitochondria is a hallmark of breast, gastric, lung and oesophageal cancer. Biochem. J. 378 (2004) 17-20
121. Kwong J., Henning M., Starkov A., and Manfredi G. The mitochondrial respiratory chain is a modulator of apoptosis. J. Cell Biol. 179 (2007) 1163-1177
122. Kurtoglu M., and Lampidis T. From delocalized lipophilic cations to hypoxia: blocking tumor cell mitochondrial function leads to therapeutic gain with glycolytic inhibitors. Mol. Nutr. Food Res. 53 (2009) 68-75
123. Propper D., Braybrooke J., Taylor D., Lodi R., Styles P., Cramer J., Collins W., Levitt N., Talbot D., Ganesan T., Harris A., and Phase I. trial of the selective mitochondrial toxin MKT077 in chemo-resistant solid tumours. Ann. Oncol. 10 (1999) 923-927
124. Jones L., Narayan K., Shapiro C., and Sweatman T. Rhodamine-123: therapy for hormone refractory prostate cancer, a phase I clinical trial. J. Chemother. 17 (2005) 435-440
125. DeBerardinis R.J., Sayed N., Ditsworth D., and Thompson C.B. Brick by brick: metabolism and tumor cell growth. Curr. Opin. Genet. Dev. 18 (2008) 54-61
126. Patel M.S., and Korotchkina L.G. Regulation of mammalian pyruvate dehydrogenase complex by phosphorylation: complexity of multiple phosphorylation sites and kinases. Exp. Mol. Med. 33 (2001) 191-197
127. Roche T.E., and Hiromasa Y. Pyruvate dehydrogenase kinase regulatory mechanisms and inhibition in treating diabetes, heart ischemia, and cancer. Cell Mol. Life Sci. 64 (2007) 830-849
128. Chun-Wun Lu S.C., Lin K.F., Chen Y.Y., and Tsai Lai S.J. Induction of pyruvate dehydrogenase kinase-3 by hypoxia-inducible factor-1 promotes metabolic switch and drug resistance. J. Biol. Chem. 283 (2008) 28106-28114
129. McFate T., Mohyeldin A., Lu H., Thakar J., Henriques J., Halim N.D., Wu H., Schell M.J., Tsang T.M., Teahan O., Zhou S., Califano J.A., Jeoung N.H., Harris R.A., and Verma A. Pyruvate dehydrogenase complex activity controls metabolic and malignant phenotype in cancer cells. J. Biol. Chem. 283 (2008) 22700-22708
130. Kato M., Li J., Chuang J.L., and Chuang D.T. Distinct structural mechanisms for inhibition of pyruvate dehydrogenase kinase isoforms by AZD7545, dichloroacetate, and radicicol. Structure 15 (2007) 992-1004
131. U.S. National Institutes of Health. ClinicalTrials.gov, Dichloroacetate (2009)
132. Aicher T.D., Anderson R.C., Gao J., Shetty S.S., Coppola G.M., Stanton J.L., Knorr D.C., Sperbeck D.M., Brand L.J., Vinluan C.C., Kaplan E.L., Dragland C.J., Tomaselli H.C., Islam A., Lozito R.J., Liu X., Maniara W.M., Fillers W.S., DelGrande D., Walter R.E., and Mann W.R. Secondary amides of (R)-3,3,3-trifluoro-2-hydroxy-2-methylpropionic acid as inhibitors of pyruvate dehydrogenase kinase. J. Med. Chem. 43 (2000) 236-249
133. Aicher T.D., Damon R.E., Koletar J., Vinluan C.C., Brand L.J., Gao J., Shetty S.S., Kaplan E.L., and Mann W.R. Triterpene and diterpene inhibitors of pyruvate dehydrogenase kinase (PDK). Bioorg. Med. Chem. Lett. 9 (1999) 2223-2228
134. Mann W.R., Dragland C.J., Vinluan C.C., Vedananda T.R., Bell P.A., and Aicher T.D. Diverse mechanisms of inhibition of pyruvate dehydrogenase kinase by structurally distinct inhibitors. Biochim. Biophys. Acta 1480 (2000) 283-292
135. Kadenbach B. Intrinsic and extrinsic uncoupling of oxidative phosphorylation. Biochim. Biophys. Acta 1604 (2003) 77-94
136. Newell K.J., and Tannock I.F. Reduction of intracellular pH as a possible mechanism for killing cells in acidic regions of solid tumors: effects of carbonylcyanide-3-chlorophenylhydrazone. Cancer Res. 49 (1989) 4477-4482
137. Kurosu T., Tsuji K., Kida A., Koyama T., Yamamoto M., and Miura O. Rottlerin synergistically enhances imatinib-induced apoptosis of BCR/ABL-expressing cells through its mitochondrial uncoupling effect independent of protein kinase C-delta. Oncogene 26 (2007) 2975-2987
138. Thomas R., and Kim M.H. Targeting the hypoxia inducible factor pathway with mitochondrial uncouplers. Mol. Cell Biochem. 296 (2007) 35-44
139. Anderson S., Bankier A., Barrell B., de Bruijn M., Coulson A., Drouin J., Eperon I., Nierlich D., Roe B., Sanger F., Schreier P., Smith A., Staden R., and Young I. Sequence and organization of the human mitochondrial genome. Nature 290 (1981) 457-465
140. Croteau D., and Bohr V. Repair of oxidative damage to nuclear and mitochondrial DNA in mammalian cells. J. Biol. Chem. 272 (1997) 25409-25412
141. Petros J., Baumann A., Ruiz-Pesini E., Amin M., Sun C., Hall J., Lim S., Issa M., Flanders W., Hosseini S., Marshall F., and Wallace D. mtDNA mutations increase tumorigenicity in prostate cancer. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 719-724
142. Lee H., and Wei Y. Mitochondrial DNA instability and metabolic shift in human cancers. Int. J. Mol. Sci. 10 (2009) 674-701
143. Chatterjee A., Mambo E., and Sidransky D. Mitochondrial DNA mutations in human cancer. Oncogene 25 (2006) 4663-4674
144. Jakupciak J., Maragh S., Markowitz M., Greenberg A., Hoque M., Maitra A., Barker P., Wagner P., Rom W., Srivastava S., Sidransky D., and O'Connell C. Performance of mitochondrial DNA mutations detecting early stage cancer. BMC Cancer 8 (2008) 285
145. Polyak K., Li Y., Zhu H., Lengauer C., Willson J., Markowitz S., Trush M., Kinzler K., and Vogelstein B. Somatic mutations of the mitochondrial genome in human colorectal tumours. Nat. Genet. 20 (1998) 291-293
146. Ishikawa K., Takenaga K., Akimoto M., Koshikawa N., Yamaguchi A., Imanishi H., Nakada K., Honma Y., and Hayashi J. ROS-generating mitochondrial, D.N.A., mutations can regulate tumor cell metastasis. Science 320 (2008) 661-664
147. Pollard P.J., Brière J.J., Alam N.A., Barwell J., Barclay E., Wortham N.C., Hunt T., Mitchell M., Olpin S., Moat S.J., Hargreaves I.P., Heales S.J., Chung Y.L., Griffiths J.R., Dalgleish A., McGrath J.A., Gleeson M.J., Hodgson S.V., Poulsom R., Rustin P., and Tomlinson I.P. Accumulation of Krebs cycle intermediates and over-expression of HIF1alpha in tumours which result from germline FH and SDH mutations. Hum. Mol. Genet. 14 (2005) 2231-2239
148. Baysal B.E. Krebs cycle enzymes as tumor suppressors. Drug Discov. Today Dis. Mech. 2 (2005) 247-254
149. Xie H., Valera V.A., Merino M.J., Amato A.M., Signoretti S., Linehan W.M., Sukhatme V.P., and Seth P. LDH-A inhibition, a therapeutic strategy for treatment of hereditary leiomyomatosis and renal cell cancer. Mol. Cancer Ther. 8 (2009) 626-635
150. Holmgren A. Thioredoxin. Annu. Rev. Biochem. 54 (1985) 237-271
151. Cromlish J., and Roeder R. Human transcription factor IIIC (TFIIIC). Purification, polypeptide structure, and the involvement of thiol groups in specific DNA binding. J. Biol. Chem. 264 (1989) 18100-18109
152. Ireland R., Li S., and Dougherty J. The DNA binding of purified Ah receptor heterodimer is regulated by redox conditions. Arch. Biochem. Biophys. 319 (1995) 470-480
153. Ago T., Yeh I., Yamamoto M., Schinke-Braun M., Brown J., Tian B., and Sadoshima J. Thioredoxin1 upregulates mitochondrial proteins related to oxidative phosphorylation and TCA cycle in the heart. Antioxid. Redox Signal. 8 (2006) 1635-1650
154. Baker A., Payne C., Briehl M., and Powis G. Thioredoxin, a gene found overexpressed in human cancer, inhibits apoptosis in vitro and in vivo. Cancer Res. 57 (1997) 5162-5167
155. Lincoln D., Ali Emadi E., Tonissen K., and Clarke F. The thioredoxin-thioredoxin reductase system: over-expression in human cancer. Anticancer Res. 23 (2003) 2425-2433
156. Tome M., Johnson D., Rimsza L., Roberts R., Grogan T., Miller T., Oberley L., and Briehl M. A redox signature score identifies diffuse large B-cell lymphoma patients with a poor prognosis. Blood 106 (2005) 3594-3601
157. Yokomizo A., Ono M., Nanri H., Makino Y., Ohga T., Wada M., Okamoto T., Yodoi J., Kuwano M., and Kohno K. Cellular levels of thioredoxin associated with drug sensitivity to cisplatin, mitomycin C, doxorubicin, and etoposide. Cancer Res. 55 (1995) 4293-4296
158. Yamada Y., Nakamura H., Adachi T., Sannohe S., Oyamada H., Kayaba H., Yodoi J., and Chihara J. Elevated serum levels of thioredoxin in patients with acute exacerbation of asthma. Immunol. Lett. 86 (2003) 199-205
159. Urig S., and Becker K. On the potential of thioredoxin reductase inhibitors for cancer therapy. Semin. Cancer Biol. 16 (2006) 452-465
160. Mukherjee A., and Martin S. The thioredoxin system: a key target in tumour and endothelial cells. Br. J. Radiol. 81 Spec No 1 (2008) S57-68
161. Berners-Price S.J., and Filipovska A. The design of gold-based, mitochondria-targeted chemotherapeutics. Aust. J. Chem. 61 (2008) 661-668
162. Hickey J.L., Ruhayel R.A., Barnard P.J., Baker M.V., Berners-Price S.J., and Filipovska A. Mitochondria-targeted chemotherapeutics: the rational design of gold(I) N-heterocyclic carbene complexes that are selectively toxic to cancer cells and target protein selenols in preference to thiols. J. Am. Chem. Soc. 130 (2008) 12570-12571
163. Czyz A., Scewczyk A., Nalecz M.J., and Wojtczak L. The role of mitochondrial potassium fluxes in controlling the protonmotive force in energized mitochondria. Biochem. Biophys. Res. Commun. 210 (1995) 98-104
164. Bonnet S., Archer S.L., Allalunis-Turner J., Haromy A., Beaulieu C., Thompson R., Lee C.T., Lopaschuk G.D., Puttagunta L., Bonnet S., Harry G., Hashimoto K., Porter C.J., Andrade M.A., Thebaud B., and Michelakis E.D. A mitochondria-K+ channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth. Cancer Cells 11 (2007) 37-51
165. ATP channel as a receptor for potassium channel openers. J. Biol. Chem. 271 (1996) 8796-8799
166. Lee Y.S., Sayeed M.M., and Wurster R.D. In vitro antitumor activity of cromakalim in human brain tumor cells. Pharmacol. 49 (1994) 69-74
167. Abdul M., Santo A., and Hoosein N. Activity of potassium channel-blockers in breast cancer. Anticancer Res. 23 (2003) 3347-3351
168. Qian X., Li J., Ding J., Wang Z., Duan L., and Hu G. Glibenclamide exerts an antitumor activity through reactive oxygen species-c-jun NH2-terminal kinase pathway in human gastric cancer cell line MGC-803. Biochem. Pharmacol. 76 (2008) 1705-1715
169. Garlid K.D., Paucek P., Yarov-Yarovoy V., Murray H.N., Darbenzio R.B., D'Alonzo A.J., Lodge N.J., Smith M.A., and Grover G.J. Cardioprotective effect of diazoxide and its interaction with mitochondrial ATP-sensitive K+ channels. Circ. Res. 81 (1997) 1072-1082
170. Tai K.K., McCrossan Z.A., and Abbott G.W. Activation of mitochondrial ATP-sensitive potassium channels increases cell viability against rotenone-induced cell death. J. Neurochem. 84 (2003) 1193-1200
171. Cao C., Healey S., Amaral A., Lee-Couture A., Wan S., Kouttab N., Chu W., and Wan Y. ATP-sensitive potassium channel: a novel target for protection against UV-induced human skin cell damage. J. Cell. Physiol. 212 (2007) 252-263
172. Kopustinskienea D.M., Polleselloc P., and Sarisd N.E.L. Potassium-specific effects of levosimendan on heart mitochondria. Biochem. Pharmacol. 68 (2004) 807-812
173. Debska G., Kicinska A., Dobrucki J., Dworakowska B., Nurowska E., Skalska J., Dolowy K., and Szewczyk A. Large-conductance K+ channel openers NS1619 and NS004 as inhibitors of mitochondrial function in glioma cells. Biochem. Pharmacol. 65 (2003) 1827-1834
174. Holmuhamedov E., Lewis L., Bienengraeber M., Holmuhamedova M., Jahangir A., and Terzic A. Suppression of human tumor cell proliferation through mitochondrial targeting. FASEB J. 16 (2002) 1010-1016
175. Tsujimoto Y., and Shimizu S. Role of the mitochondrial membrane permeability transition in cell death. Apoptosis 12 (2007) 835-840
176. Green D., and Evan G. A matter of life and death. Cancer Cells 1 (2002) 19-30
177. Desagher S., and Martinou J. Mitochondria as the central control point of apoptosis. Trends Cell Biol. 10 (2000) 369-377
178. Tsujimoto Y. Cell death regulation by the Bcl-2 protein family in the mitochondria. J. Cell. Physiol. 195 (2003) 158-167
179. Crompton M. On the involvement of mitochondrial intermembrane junctional complexes in apoptosis. Curr. Med. Chem. 10 (2003) 1473-1484
180. Crompton M., Virji S., and Ward J. Cyclophilin-D binds strongly to complexes of the voltage-dependent anion channel and the adenine nucleotide translocase to form the permeability transition pore. Eur. J. Biochem. 258 (1998) 729-735
181. Basso E., Fante L., Fowlkes J., Petronilli V., Forte M., and Bernardi P. Properties of the permeability transition pore in mitochondria devoid of Cyclophilin D. J. Biol. Chem. 280 (2005) 18558-18561
182. Zamzami N., and Kroemer G. The mitochondrion in apoptosis: how Pandora's box opens. Nat. Rev., Mol. Cell Biol. 2 (2001) 67-71
183. Kokoszka J., Waymire K., Levy S., Sligh J., Cai J., Jones D., MacGregor G., and Wallace D. The ADP/ATP translocator is not essential for the mitochondrial permeability transition pore. Nature 427 (2004) 461-465
184. Baines C., Kaiser R., Sheiko T., Craigen W., and Molkentin J. Voltage-dependent anion channels are dispensable for mitochondrial-dependent cell death. Nat. Cell Biol. 9 (2007) 550-555
185. Huizing M., Ruitenbeek W., van den Heuvel L., Dolce V., Iacobazzi V., Smeitink J., Palmieri F., and Trijbels J. Human mitochondrial transmembrane metabolite carriers: tissue distribution and its implication for mitochondrial disorders. J. Bioenerg. Biomembranes 30 (1998) 277-284
186. Guo X., Smith P., Cognon B., D'Arcangelis D., Dolginova E., and Mannella C. Molecular design of the voltage-dependent, anion-selective channel in the mitochondrial outer membrane. J. Struct. Biol. 114 (1995) 41-59
187. Narita M., Shimizu S., Ito T., Chittenden T., Lutz R., Matsuda H., and Tsujimoto Y. Bax interacts with the permeability transition pore to induce permeability transition and cytochrome c release in isolated mitochondria. Proc. Natl. Acad. Sci. U. S. A. 95 (1998) 14681-14686
188. Shimizu S., Narita M., and Tsujimoto Y. Bcl-2 family proteins regulate the release of apoptogenic cytochrome c by the mitochondrial channel VDAC. Nature 399 (1999) 483-487
189. Simamura E., Shimada H., Hatta T., and Hirai K. Mitochondrial voltage-dependent anion channels (VDACs) as novel pharmacological targets for anti-cancer agents. J. Bioenerg. Biomembranes 40 (2008) 213-217
190. Thinnes F. Human type-1, V.D.A.C., a cisplatin target involved in either apoptotic pathway. Mol. Genet. Metab. 97 (2009) 163
191. Simamura E., Hirai K., Shimada H., Koyama J., Niwa Y., and Shimizu S. Furanonaphthoquinones cause apoptosis of cancer cells by inducing the production of reactive oxygen species by the mitochondrial voltage-dependent anion channel. Cancer Biol. Ther. 5 (2006) 1523-1529
192. Sarin S., Shami S., Shields D., Scurr J., and Smith P. Selection of amputation level: a review. Eur. J. Vasc. Surg. 5 (1991) 611-620
193. Belzacq A., and Brenner C. The adenine nucleotide translocator: a new potential chemotherapeutic target. Curr. Drug Targets 4 (2003) 517-524
194. Belzacq A., El Hamel C., Vieira H., Cohen I., Haouzi D., Métivier D., Marchetti P., Brenner C., and Kroemer G. Adenine nucleotide translocator mediates the mitochondrial membrane permeabilization induced by lonidamine, arsenite and CD437. Oncogene 20 (2001) 7579-7587
195. Le Bras M., Borgne-Sanchez A., Touat Z., El Dein O., Deniaud A., Maillier E., Lecellier G., Rebouillat D., Lemaire C., Kroemer G., Jacotot E., and Brenner C. Chemosensitization by knockdown of adenine nucleotide translocase-2. Cancer Res. 66 (2006) 9143-9152
196. Galat A., and Metcalfe S. Peptidylproline cis/trans isomerases. Prog. Biophys. Mol. Biol. 63 (1995) 67-118
197. Nakagawa T., Shimizu S., Watanabe T., Yamaguchi O., Otsu K., Yamagata H., Inohara H., Kubo T., and Tsujimoto Y. Cyclophilin D-dependent mitochondrial permeability transition regulates some necrotic but not apoptotic cell death. Nature 434 (2005) 652-658
198. Connern C., and Halestrap A. Purification and N-terminal sequencing of peptidyl-prolyl cis-trans-isomerase from rat liver mitochondrial matrix reveals the existence of a distinct mitochondrial cyclophilin. Biochem. J. 284 Pt 2 (1992) 381-385
199. Machida K., Ohta Y., and Osada H. Suppression of apoptosis by cyclophilin D via stabilization of hexokinase II mitochondrial binding in cancer cells. J. Biol. Chem. 281 (2006) 14314-14320
200. Eliseev R., Malecki J., Lester T., Zhang Y., Humphrey J., Gunter T., and Cyclophilin D. interacts with Bcl2 and exerts an anti-apoptotic effect. J. Biol. Chem. 284 (2009) 9692-9699
201. Lowe S.W., and Lin A.W. Apoptosis in cancer. Carcinogenesis 21 (2000) 485-495
202. Youle R.J., and Strasser A. The BCL-2 protein family: opposing activities that mediate cell death. Nat. Rev., Mol. Cell Biol. 9 (2008) 47-59
203. Kang M.H., and Reynolds C.P. Bcl-2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy. Clin. Cancer Res. 15 (2009) 1126-1132
204. Azmi A.S., and Mohammad R.M. Non-peptidic small molecule inhibitors against Bcl-2 for cancer therapy. J. Cell. Physiol. 218 (2009) 13-21
205. Lessene G., Czabotar P.E., and Colman P.M. Bcl-2 family antagonists for cancer therapy. Nat. Rev. Drug Dis. 7 (2008) 989-1000
206. vanLoo G., Saelens X., vanGurp M., MacFarlane M., Martin S.J., and Vandenabeele P. The role of mitochondrial factors in apoptosis: a Russian roulette with more than one bullet. Cell Death Differ. 9 (2002) 1031-1042
207. Rothe M., Pan M.G., Henzel W.J., Ayres T.M., and Goeddel D.V. The TNFR2-TRAF signaling complex contains two novel proteins related to baculoviral inhibitor of apoptosis proteins. Cell 83 (1995) 1243-1252
208. Shiozaki E.N., Chai J., Rigotti D.J., Riedl S.J., Li P., Srinivasula S.M., Alnemri E.S., Fairman R., and Shi Y. Mechanism of XIAP-mediated inhibition of caspase-9. Mol. Cell 11 (2003) 519-527
209. Chai J., Shiozaki E., Srinivasula S.M., Wu Q., Datta P., Alnemri E.S., and Shi Y. Structural basis of caspase-7 inhibition by XIAP. Cell 104 (2001) 769-780
210. Riedl S.J., Renatus M., Schwarzenbacher R., Zhou Q., Sun C., Fesik S.W., Liddington R.C., and Salvesen G.S. Structural basis for the inhibition of caspase-3 by XIAP. Cell 104 (2001) 791-800
211. Du C., Fang M., Li Y., Li L., and Wang X. Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition. Cell 102 (2000) 33-42
212. Verhagen A.M., Ekert P.G., Pakusch M., Silke J., Connolly L.M., Reid G.E., Moritz R.L., Simpson R.J., and Vaux D.L. Identification of DIABLO, a mammalian protein that promotes apoptosis by binding to and antagonizing IAP proteins. Cell 102 (2000) 43-53
213. LaCasse E.C., Baird S., Korneluk R.G., and MacKenzie A.E. The inhibitors of apoptosis (IAPs) and their emerging role in cancer. Oncogene 17 (1998) 3247-3259
214. Mizutani Y., Nakanishi H., Yamamoto K., Li Y.N., Matsubara H., Mikami K., Okihara K., Kawauchi A., Bonavida B., and Miki T. Downregulation of Smac/DIABLO expression in renal cell carcinoma and its prognostic significance. J. Clin. Oncol. 23 (2005) 448-454
215. Sekimura A., Konishi A., Mizuno K., Kobayashi Y., Sasaki H., Yano M., Fukai I., and Fujii Y. Expression of Smac/DIABLO is a novel prognostic marker in lung cancer. Oncol. Rep. 11 (2004) 797-802
216. Espinosa M., Cantu D., Lopez C.M., DelaGarza J.G., Maldonado V.A., and Melendez-Zajgla J. SMAC is expressed de novo in a subset of cervical cancer tumors. BMC Cancer (2004) 4
217. Arellano-Llamas A., Garcia F.J., Perez D., Cantu D., Espinosa M., DelaGarza J.G., Maldonado V., and Melendez-Zajgla J. High Smac/DIABLO expression is associated with early local recurrence of cervical cancer. BMC Cancer (2006) 6
218. Fandy T.E., Shankar S., and Srivastava R.K. Smac/DIABLO enhances the therapeutic potential of chemotherapeutic drugs and irradiation, and sensitizes TRAIL-resistant breast cancer cells. Mol. Cancer (2008) 7
219. Petrucci E., Pasquini L., Petronelli A., Saulle E., Mariani G., Riccioni R., Biffoni M., Ferretti G., Benedetti-Panici P., Cognetti F., Scambia G., Humphreys R., Peschle C., and Testa U. A small molecule Smac mimic potentiates TRAIL-mediated cell death of ovarian cancer cells. Gynecol. Oncol. 105 (2007) 481-492
220. Usuda J., Chiu S.M., Azizuddin K., Xue L.Y., Lam M., Nieminen A.L., and Oleinick N.L. Promotion of photodynamic therapy-induced apoptosis by the mitochondrial protein Smac/DIABLO: dependence on Bax. Photochem. Photobiol. 76 (2002) 217-223
221. Petersen S.L., Wang L., Yalchin-Chin A., Li L., Peyton M., Minna J., Harran P., and Wang X. Autocrine TNFalpha signaling renders human cancer cells susceptible to Smac-mimetic-induced apoptosis. Cancer Cells 12 (2007) 445-456
222. Vince J.E., Wong W.W., Khan N., Feltham R., Chau D., Ahmed A.U., Benetatos C.A., Chunduru S.K., Condon S.M., McKinlay M., Brink R., Leverkus M., Tergaonkar V., Schneider P., Callus B.A., Koentgen F., Vaux D.L., and Silke J. IAP antagonists target cIAP1 to induce TNFalpha-dependent apoptosis. Cell 131 (2007) 682-693
223. Varfolomeev E., Blankenship J.W., Wayson S.M., Fedorova A.V., Kayagaki N., Garg P., Zobel K., Dynek J.N., Elliott L.O., Wallweber H.J., Flygare J.A., Fairbrother W.J., Deshayes K., Dixit V.M., and Vucic D. IAP antagonists induce autoubiquitination of c-IAPs, NF-kappaB activation, and TNFalpha-dependent apoptosis. Cell 131 (2007) 669-681
224. Ascenta Therapeutics. Development Pipeline, IAP inhibitors or Smac mimetics: AT-406 (2009)
225. Wu G., Chai J., Suber T.L., Wu J.W., Du C., Wang X., and Shi Y. Structural basis of IAP recognition by Smac/DIABLO. Nature 408 (2000) 1008-1012
226. Kipp R.A., Case M.A., Wist A.D., Cresson C.M., Carrell M., Griner E., Wiita A., Albiniak P.A., Chai J., Shi Y., Semmelhack M.F., and McLendon G.L. Molecular targeting of inhibitor of apoptosis proteins based on small molecule mimics of natural binding partners. Biochem. 41 (2002) 7344-7349
227. Oost T.K., Sun C., Armstrong R.C., Al-Assaad A.S., Betz S.F., Deckwerth T.L., Ding H., Elmore S.W., Meadows R.P., Olejniczak E.T., Oleksijew A., Oltersdorf T., Rosenberg S.H., Shoemaker A.R., Tomaselli K.J., Zou H., and Fesik S.W. Discovery of potent antagonists of the antiapoptotic protein XIAP for the treatment of cancer. J. Med. Chem. 47 (2004) 4417-4426
228. Sun H., Nikolovska-Coleska Z., Chen J., Yang C.Y., Tomita Y., Pan H., Yoshioka Y., Krajewski K., Roller P.P., and Wang S. Structure-based design, synthesis and biochemical testing of novel and potent Smac peptido-mimetics. Bioorg. Med. Chem. Lett. 15 (2005) 793-797
229. Zobel K., Wang L., Varfolomeev E., Franklin M.C., Elliott L.O., Wallweber H.J., Okawa D.C., Flygare J.A., Vucic D., Fairbrother W.J., and Deshayes K. Design, synthesis, and biological activity of a potent Smac mimetic that sensitizes cancer cells to apoptosis by antagonizing IAPs. ACS Chem. Biol. 1 (2006) 525-533
230. Park C.M., Sun C., Olejniczak E.T., Wilson A.E., Meadows R.P., Betz S.F., Elmorea S.W., and Fesik S.W. Non-peptidic small molecule inhibitors of XIAP. Bioorg. Med. Chem. Lett. 15 (2005) 771-775
231. Sun H., Nikolovska-Coleska Z., Yang C.Y., Xu L., Liu M., Tomita Y., Pan H., Yoshioka Y., Krajewski K., Roller P.P., and Wang S. Structure-based design of potent, conformationally constrained Smac mimetics. J. Am. Chem. Soc. 126 (2004) 16686-16687
232. Sun H., Nikolovska-Coleska Z., Yang C.Y., Xu L., Tomita Y., Krajewski K., Roller P.P., and Wang S. Structure-based design, synthesis, and evaluation of conformationally constrained mimetics of the second mitochondria-derived activator of caspase that target the X-linked inhibitor of apoptosis protein/caspase-9 interaction site. J. Med. Chem. 47 (2004) 4147-4150
233. Sun H., Stuckey J.A., Nikolovska-Coleska Z., Qin D., Meagher J.L., Qiu S., Lu J., Yang C.Y., Saito N.G., and Wang S. Structure-based design, synthesis, evaluation, and crystallographic studies of conformationally constrained Smac mimetics as inhibitors of the X-linked inhibitor of apoptosis protein (XIAP). J. Med. Chem. 51 (2008) 7169-7180
234. Sun H., Nikolovska-Coleska Z., Lu J., Qiu S., Yang C.Y., Gao W., Meagher J., Stuckey J., and Wang S. Design, synthesis, and evaluation of a potent, cell-permeable, conformationally constrained second mitochondria derived activator of caspase (Smac) mimetic. J. Med. Chem. 49 (2006) 7916-7920
235. Nikolovska-Coleska Z., Meagher J.L., Jiang S., Kawamoto S.A., Gao W., Yi H., Qin D., Roller P.P., Stuckey J.A., and Wang S. Design and characterization of bivalent Smac-based peptides as antagonists of XIAP and development and validation of a fluorescence polarization assay for XIAP containing both BIR2 and BIR3 domains. Anal. Biochem. 374 (2007) 87-98
236. Sun H., Nikolovska-Coleska Z., Lu J., Meagher J.L., Yang C.Y., Qiu S., Tomita Y., Ueda Y., Jiang S., Krajewski K., Roller P.P., Stuckey J.A., and Wang S. Design, synthesis, and characterization of a potent, nonpeptide, cell-permeable, bivalent Smac mimetic that concurrently targets both the BIR2 and BIR3 domains in XIAP. J. Am. Chem. Soc. 129 (2007) 15279-15294
237. Lu J., Bai L., Sun H., Nikolovska-Coleska Z., McEachern D., Qiu S., Miller R.S., Yi H., Shangary S., Sun Y., Meagher J.L., Stuckey J.A., and Wang S. SM-164: a novel, bivalent Smac mimetic that induces apoptosis and tumor regression by concurrent removal of the blockade of cIAP-1/2 and XIAP. Cancer Res. (2008) 68
238. Murphy M. Targeting lipophilic cations to mitochondria. Biochim. Biophys. Acta. 1777 (2008) 1028-1031
239. Ross M., Kelso G., Blaikie F., James A., Cochemé H., Filipovska A., Da Ros T., Hurd T., Smith R., and Murphy M. Lipophilic triphenylphosphonium cations as tools in mitochondrial bioenergetics and free radical biology. Biochem. (Mosc). 70 (2005) 222-230
240. Dubois R., Lin C., and Beisler J. Synthesis and antitumor properties of some isoindolylalkylphosphonium salts. J. Med. Chem. 21 (1978) 303-306
241. Trapp S., and Horobin R. A predictive model for the selective accumulation of chemicals in tumor cells. Eur. Biophys. J. 34 (2005) 959-966
242. Asin-Cayuela J., Manas A., James A., Smith R., and Murphy M. Fine-tuning the hydrophobicity of a mitochondria-targeted antioxidant. FEBS Lett. 571 (2004) 9-16
243. Min J., Biswal S., Deroose C., and Gambhir S. Tetraphenylphosphonium as a novel molecular probe for imaging tumors. J. Nucl. Med. 45 (2004) 636-643
244. Madar I., Ravert H., Nelkin B., Abro M., Pomper M., Dannals R., and Frost J. Characterization of membrane potential-dependent uptake of the novel PET tracer 18F-fluorobenzyl triphenylphosphonium cation. Eur. J. Nucl. Med. Mol. Imaging 34 (2007) 2057-2065
245. Wang J., Yang C., Kim Y., Sreerama S., Cao Q., Li Z., He Z., Chen X., and Liu S. 64Cu-Labeled triphenylphosphonium and triphenylarsonium cations as highly tumor-selective imaging agents. J. Med. Chem. 50 (2007) 5057-5069
246. Kim Y., Yang C., Wang J., Wang L., Li Z., Chen X., and Liu S. Effects of targeting moiety, linker, bifunctional chelator, and molecular charge on biological properties of 64Cu-labeled triphenylphosphonium cations. J. Med. Chem. 51 (2008) 2971-2984
247. Savi A., Gerundini P., Zoli P., Maffioli L., Compierchio A., Colombo F., Matarrese M., and Deutsch E. Biodistribution of Tc-99m methoxy-isobutyl-isonitrile (MIBI) in humans. Eur. J. Nucl. Med. Mol. Imaging 15 (1989) 597-600
248. Srivastava P., Hay H., and Knapp F.J. Effects of alkyl and aryl substitution on the myocardial specificity of radioiodinated phosphonium, arsonium, and ammonium cations. J. Med. Chem. 28 (1985) 901-904
249. Kubo A., Nakamura K., Sanmiya T., Shimizu S., Hashimoto S., Iwanaga S., Handa S., and Torizuka K. [Phase I clinical study on 99mTc-MIBI]. Kaku Igaku 28 (1991) 1133-1142
250. Gommans G., van der Zant F., van Dongen A., Boer R., Teule G., and de Waard J. (99M)Technetium-sestamibi scintimammography in non-palpable breast lesions found on screening X-ray mammography. Eur. J. Surg. Oncol. 33 (2007) 23-27
251. Usmani S., Niaz K., Maseeh-Uz-Zaman S., Kamal K., Niyaz J., Mehboob A., Hashmi S., and Habib H. Hashmi, Role of 99mTc-MIBI scintimammography and X-ray mammography in the diagnosis of locoregional recurrence of breast cancer. J. Pak. Med. Assoc. 57 (2007) 172-175
252. Usmani S., Khan H., Niaz K., Uz-Zaman M., Niyaz K., Javed A., al Mohannadi S., Abu al Huda F., and Kamal S. Tc-99m-methoxy isobutyl isonitrile scintimammography: imaging postexcision biopsy for residual and multifocal breast tumor. Nucl. Med. Commun. 29 (2008) 826-829
253. Fuster D., Viñolas N., Mallafré C., Pavia J., MartÃn F., and Pons F. Tetrofosmin as predictors of tumour response. Q. J. Nucl. Med. 47 (2003) 58-62
254. Mohan H., and Miles K. Cost-effectiveness of 99mTc-sestamibi in predicting response to chemotherapy in patients with lung cancer: systematic review and meta-analysis. J. Nucl. Med. 50 (2009) 376-381
255. Sergieva S., Timcheva K., and Hadjiolov N. 99mTc-MIBI scintigraphy as a functional method for the evaluation of multidrug resistance in breast cancer patients. J. BUON 11 (2006) 61-68
256. Aloj L., Zannetti A., Caracó C., Del Vecchio S., and Salvatore M. Bcl-2 overexpression prevents 99mTc-MIBI uptake in breast cancer cell lines. Eur. J. Nucl. Med. Mol. Imaging 31 (2004) 521-527
257. Del Vecchio S., Zannetti A., Aloj L., Caracò C., Ciarmiello A., and Salvatore M. Inhibition of early 99mTc-MIBI uptake by Bcl-2 anti-apoptotic protein overexpression in untreated breast carcinoma. Eur. J. Nucl. Med. Mol. Imaging 30 (2003) 879-887
258. Agapova L., Chernyak B., Domnina L., Dugina V., Efimenko A., Fetisova E., Ivanova O., Kalinina N., Khromova N., Kopnin B., Kopnin P., Korotetskaya M., Lichinitser M., Lukashev A., Pletjushkina O., Popova E., Skulachev M., Shagieva G., Stepanova E., Titova E., Tkachuk V., Vasiliev J., and Skulachev V. Mitochondria-targeted plastoquinone derivatives as tools to interrupt execution of the aging program. 3. Inhibitory effect of SkQ1 on tumor development from p53-deficient cells. Biochem. (Mosc). 73 (2008) 1300-1316
259. Leo S., Szabadkai G., and Rizzuto R. The mitochondrial antioxidants MitoE(2) and MitoQ(10) increase mitochondrial Ca(2+) load upon cell stimulation by inhibiting Ca(2+) efflux from the organelle. Ann. N. Y. Acad. Sci. 1147 (2008) 264-274
260. Manetta A., Gamboa G., Nasseri A., Podnos Y., Emma D., Dorion G., Rawlings L., Carpenter P., Bustamante A., Patel J., and Rideout D. Novel phosphonium salts display in vitro and in vivo cytotoxic activity against human ovarian cancer cell lines. Gynecol. Oncol. 60 (1996) 203-212
261. Henderson B., and Dougherty T. How does photodynamic therapy work?. Photochem. Photobiol. 55 (1992) 145-157
262. Dougherty T., Gomer C., Henderson B., Jori G., Kessel D., Korbelik M., Moan J., and Peng Q. Photodynamic therapy. J. Natl. Cancer. Inst. 90 (1998) 889-905
263. Morgan J., and Oseroff A. Mitochondria-based photodynamic anti-cancer therapy. Adv. Drug Deliv. Rev. 49 (2001) 71-86
264. Woodburn K., Chang C., Lee S., Henderson B., and Kessel D. Biodistribution and PDT efficacy of a ketochlorin photosensitizer as a function of the delivery vehicle. Photochem. Photobiol. 60 (1994) 154-159
265. Gardner L., Smith S., and Cox T. Biosynthesis of delta-aminolevulinic acid and the regulation of heme formation by immature erythroid cells in man. J. Biol. Chem. 266 (1991) 22010-22018
266. Kessel D., and Luo Y. Photodynamic therapy: a mitochondrial inducer of apoptosis. Cell Death Differ. 6 (1999) 28-35
267. Yeh C.S., Wang J.Y., Chung F.Y., Lee S.C., Huang M.Y., Kuo C.W., Yang M.J., and Lin S.R. Significance of the glycolytic pathway and glycolysis related-genes in tumorigenesis of human colorectal cancers. Oncol. Rep. 19 (2008) 81-91
268. Gwak G.Y., Yoon J.H., Kim K.M., Lee H.S., Chung J.W., and Gores G.J. Hypoxia stimulates proliferation of human hepatoma cells through the induction of hexokinase II expression. J. Hepatol. 42 (2005) 358-364
269. Bos R., vanDerHoeven J.J., vanDerWall E., vanDerGroep P., vanDiest P.J., Comans E.F., Joshi U., Semenza G.L., Hoekstra O.S., Lammertsma A.A., and Molthoff C.F. Biologic correlates of (18)fluorodeoxyglucose uptake in human breast cancer measured by positron emission tomography. J. Clin. Oncol. 20 (2002) 379-387
270. Ko Y.H., Smith B.L., Wang Y., Pomper M.G., Rini D.A., Torbenson M.S., Hullihen J., and Pedersen P.L. Advanced cancers: eradication in all cases using 3-bromopyruvate therapy to deplete ATP. Biochem. Biophys. Res. Commun. 324 (2004) 269-275
271. Catherino W.H., Mayers C.M., Mantzouris T., Armstrong A.Y., Linehan W.M., and Segars J.H. Compensatory alterations in energy homeostasis characterized in uterine tumors from hereditary leiomyomatosis and renal cell cancer. Fertil. Steril. 88 (2007) 1039-1048
272. Li C., Xiao Z., Chen Z., Zhang X., Li J., Wu X., Li X., Yi H., Li M., Zhu G., and Liang S. Proteome analysis of human lung squamous carcinoma. Proteomics 6 (2006) 547-558
273. T.J. Lampidis, W. Priebe, Cancer chemotherapy with 2-deoxy-D-glucose, U.S. Patent 6670330, 2003.
274. Mikuriya K., Kuramitsu Y., Ryozawa S., Fujimoto M., Mori S., Oka M., Hamano K., Okita K., Sakaida I., and Nakamura K. Expression of glycolytic enzymes is increased in pancreatic cancerous tissues as evidenced by proteomic profiling by two-dimensional electrophoresis and liquid chromatography-mass spectrometry/mass spectrometry. Int. J. Oncol. 4 (2007) 849-855
275. Rondinelli R.H., Epner D.E., and Tricoli J.V. Increased glyceraldehyde-3-phosphate dehydrogenase gene expression in late pathological stage human prostate cancer. Prostate Cancer Prostatic Dis. 1 (1997) 66-72
276. U.S. National Institutes of Health. Clinical Trails. gov, Arsenic trioxide (2009)
277. Ascenta Therapeutics. Development Pipeline, Inhibitors of Bcl-2 family of proteins-AT101 (2009)
278. Kumagai S., Narasaki R., Hasumi K., and Glucose-dependent active A.T.P. depletion by koningic acid kills high-glycolytic cells. Biochem. Biophys. Res. Commun. 365 (2008) 362-368
279. Hwang T.L., Liang Y., Chien K.Y., and Yu J.S. Overexpression and elevated serum levels of phosphoglycerate kinase 1 in pancreatic ductal adenocarcinoma. Proteomics 6 (2006) 2259-2272
280. Giatromanolaki A., Koukourakis M.I., Pezzella F., Sivridis E., Turley H., Harris A.L., and Gatter K.C. Lactate dehydrogenase 5 expression in non-Hodgkin B-cell lymphomas is associated with hypoxia regulated proteins. Leuk. Lymphoma 49 (2008) 2181-2186
281. Rodríguez-Enríquez S., Marín-Hernández A., Gallardo-Pérez J.C., Carreño-Fuentes L., and Moreno-Sánchez R. Targeting of cancer energy metabolism. Mol. Nutr. Food Res. 53 (2009) 29-48
282. Wigfield S.M., Winter S.C., Giatromanolaki A., Taylor J., Koukourakis M.L., and Harris A.L. PDK-1 regulates lactate production in hypoxia and is associated with poor prognosis in head and neck squamous cancer. Br. J. Cancer 98 (2008) 1975-1984
283. Chen H., Yue J.X., Yang S.H., Ding H., Zhao R.W., and Zhang S. Overexpression of transketolase-like gene 1 is associated with cell proliferation in uterine cervix cancer. J. Exp. Clin. Cancer Res. (2009) 28
284. Schultz H., Kähler D., Branscheid D., Vollmer E., Zabel P., and Goldmann T. TKTL1 is overexpressed in a large portion of non-small cell lung cancer specimens. Diagn. Pathol. (2008) 3
285. Földi M., Stickeler E., Bau L., Kretz O., Watermann D., Gitsch G., Kayser G., Hausen A.Z., and Coy J.F. Transketolase protein TKTL1 overexpression: a potential biomarker and therapeutic target in breast cancer. Oncol. Rep. 17 (2007) 841-845
286. Chen C., Pore N., Behrooz A., Ismail-Beigi F., and Maity A. Regulation of glut1 mRNA by hypoxia-inducible factor-1. Interaction between H-ras and hypoxia. J. Biol. Chem. 276 (2000) 9519-9525
287. O'Rourke J.F., Pugh C.W., Bartlett S.M., and Ratcliffe P.J. Identification of hypoxically inducible mRNAs in HeLa cells using differential-display PCR. Role of hypoxia-inducible factor-1. Eur. J. Biochem. 241 (1996) 403-410
288. Iyer N.V., Kotch L.E., Agani F., Leung S.W., Laughner E., Wenger R.H., Gassmann M., Gearhart J.D., Lawler A.M., Yu A.Y., and Semenza G.L. Cellular and developmental control of O2 homeostasis by hypoxia-inducible factor 1 alpha. Genes Dev. 12 (1998) 149-162
289. Mathupala S.P., Rempel A., and Pedersen P.L. Glucose catabolism in cancer cells: identification and characterization of a marked activation response of the type II hexokinase gene to hypoxic conditions. J. Biol. Chem. 276 (2001) 43407-43412
290. Funasaka T., Yanagawa T., Hogan V., and Raz A. Regulation of phosphoglucose isomerase/autocrine motility factor expression by hypoxia. FASEB J. 19 (2005) 1422-1430
291. Gess B., Hofbauer K.H., Deutzmann R., and Kurtz A. Hypoxia up-regulates triosephosphate isomerase expression via a HIF-dependent pathway. Eur. J. Phys. 448 (2004) 175-180
292. Graven K.K., Troxler R.F., Kornfeld H., Panchenko M.V., and Farber H.W. Regulation of endothelial cell glyceraldehyde-3-phosphate dehydrogenase expression by hypoxia. J. Biol. Chem. 269 (1994) 24446-24453
293. Ptashne K.A., Morin M.E., Hance A., and Robin E.D. Increased biosynthesis of pyruvate kinase under hypoxic conditions in mammalian cells. Biochim. Biophys. Acta 844 (1985) 19-23
294. Minchenko O., Opentanova I., and Caro J. Hypoxic regulation of the 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase gene family (PFKFB-1-4) expression in vivo. FEBS Lett. 554 (2003) 265-270
295. Firth J.D., Ebert B.L., and Ratcliffe P.J. Hypoxic regulation of lactate dehydrogenase A. Interaction between hypoxia-inducible factor 1 and cAMP response elements. J. Biol. Chem. 270 (1995) 21021-21027
296. Ullah M.S., Davies A.J., and Halestrap A.P. The plasma membrane lactate transporter MCT4, but not MCT1, is up-regulated by hypoxia through a HIF-1alpha-dependent mechanism. J. Biol. Chem. 281 (2006) 9030-9037
297. Kim J.W., Tchernyshyov I., Semenza G.L., and Dang C.V. HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia. Cell Metab. 3 (2006) 177-185
298. Papandreou I., Cairns R.A., Fontana L., Lim A.L., and Denko N.C. HIF-1 mediates adaptation to hypoxia by actively downregulating mitochondrial oxygen consumption. Cell Metab. 3 (2006) 187-197
299. Zhang H., Gao P., Fukuda R., Kumar G., Krishnamachary B., Zeller K.I., Dang C.V., and Semenza G.L. HIF-1 inhibits mitochondrial biogenesis and cellular respiration in VHL-deficient renal cell carcinoma by repression of C-MYC activity. Cancer Cells 11 (2007) 407-420
300. Fukuda R., Zhang H., Kim J.W., Shimoda L., Dang C.V., and Semenza G.L. HIF-1 regulates cytochrome oxidase subunits to optimize efficiency of respiration in hypoxic cells. Cell 129 (2007) 111-122
301. Kong D., Park E.J., Stephen A.G., Calvani M., Cardellina J.H., Monks A., Fisher R.J., Shoemaker R.H., and Melillo G. Echinomycin, a small-molecule inhibitor of hypoxia-inducible factor-1 DNA-binding activity. Cancer Res. 65 (2005) 9047-9055
302. Olenyuk B.Z., Zhang G.J., Klco J.M., Nickols N.G., Kaelin Jr. W.G., and Dervan P.B. Inhibition of vascular endothelial growth factor with a sequence-specific hypoxia response element antagonist. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 16768-16773
303. Kunghor A.L., Zabludoff S.D., France D.S., Freedman S.J., Tanner E.A., Vieira A., Cornell-Kennon S., Lee J., Wang B., Wang J., Memmert K., Naegeli H.U., Petersen F., Eck M.J., Bair K.W., Wood A.W., and Livingston D.M. Small molecule blockade of transcriptional coactivation of the hypoxia-inducible factor pathway. Cancer Cells 6 (2004) 33-43
304. Dikmen Z.G., Gellert G.C., Dogan P., Yoon H., Lee Y.B., Ahn C.H., and Shay J.W. In vivo and in vitro effects of a HIF-1alpha inhibitor, RX-0047. J. Cell Biochem. 104 (2008) 985-994
305. Li S.H., Shin D.H., Chun Y.S., Lee M.K., Kim M.S., and Park J.W. A novel mode of action of YC-1 in HIF inhibition: stimulation of FIH-dependent p300 dissociation from HIF-1{alpha}. Mol. Cancer Ther. 7 (2008) 3729-3738
306. Koh M.Y., Spivak-Kroizman T., Venturini S., Welsh S., Williams R.R., Kirkpatrick D.L., and Powis G. Molecular mechanisms for the activity of PX-478, an antitumor inhibitor of the hypoxia-inducible factor-1alpha. Mol. Cancer Ther. 7 (2008) 90-100
307. Tan C., Noronha R.G.d., Roecker A.J., Pyrzynska B., Khwaja F., Zhang Z., Zhang H., Teng Q., Nicholson A.C., Giannakakou P., Zhou W., Olson J.J., Pereira M.M., Nicolaou K.C., and Meir E.G.V. Identification of a novel small-molecule inhibitor of the hypoxia-inducible factor 1 pathway. Cancer Res. 65 (2005) 605-612
308. Rapisarda A., Uranchimeg B., Scudiero D.A., Selby M., Sausville E.A., Shoemaker R.H., and Melillo G. Identification of small molecule inhibitors of hypoxia-inducible factor 1 transcriptional activation pathway. Cancer Res. 62 (2002) 4316-4324
309. Chau N.M., Rogers P., Aherne W., Carroll V., Collins I., McDonald E., Workman P., and Ashcroft M. Identification of novel small molecule inhibitors of hypoxia-inducible factor-1 that differentially block hypoxia-inducible factor-1 activity and hypoxia-inducible factor-1alpha induction in response to hypoxic stress and growth factors. Cancer Res. 65 (2005) 4918-4928
310. Park E.J., Kong D., Fisher R., Cardellina J., Shoemaker R.H., and Melillo G. Targeting the PAS-A domain of HIF-1alpha for development of small molecule inhibitors of HIF-1. Cell Cycle 5 (2006) 1847-1853
311. Chih H., Chiu H., Tang K., Chang F., and Wu Y. Bullatacin, a potent antitumor annonaceous acetogenin, inhibits proliferation of human hepatocarcinoma cell line 2.2.15 by apoptosis induction. Life Sci. 69 (2001) 1321-1331
312. Holschneider C., Johnson M., Knox R., Rezai A., Ryan W., and Montz F. Bullatacin-in vivo and in vitro experience in an ovarian cancer model. Cancer Chemother. Pharmacol. 34 (1994) 166-170
313. Oberlies N., Croy V., Harrison M., and McLaughlin J. The Annonaceous acetogenin bullatacin is cytotoxic against multidrug-resistant human mammary adenocarcinoma cells. Cancer Lett. 115 (1997) 73-79
314. Chapuis J., Khdour O., Cai X., Lu J., and Hecht S. Synthesis and characterization of Deltalac-acetogenins that potently inhibit mitochondrial complex I. Bioorg. Med. Chem. 17 (2009) 2204-2209
315. Hsia T., Yang J., Chen G., Chiu T., Lu H., Yang M., Yu F., Liu K., Lai K., Lin C., and Chung J. The roles of endoplasmic reticulum stress and Ca2+ on rhein-induced apoptosis in A-549 human lung cancer cells. Anticancer Res. 29 (2009) 309-318
316. Ip S.W., Weng Y.S., Lin S.Y., Mei-Dueyang N.Y., Tang C.C.S., and Chung J.G. The role of Ca+2 on rhein-induced apoptosis in human cervical cancer Ca Ski cells. Anticancer Res. 27 (2007) 379-389
317. Lin M., Chen S., Lu Y., Liang R., Ho Y., Yang C., and Chung J. Rhein induces apoptosis through induction of endoplasmic reticulum stress and Ca2+-dependent mitochondrial death pathway in human nasopharyngeal carcinoma cells. Anticancer Res. 27 (2007) 3313-3322
318. Wartenberg M., Hoffmann E., Schwindt H., Grünheck F., Petros J., Arnold J., Hescheler J., and Sauer H. Reactive oxygen species-linked regulation of the multidrug resistance transporter P-glycoprotein in Nox-1 overexpressing prostate tumor spheroids. FEBS Lett. 579 (2005) 4541-4549
319. Gariboldi M., Lucchi S., Caserini C., Supino R., Oliva C., and Monti E. Antiproliferative effect of the piperidine nitroxide TEMPOL on neoplastic and nonneoplastic mammalian cell lines. Free Radic. Biol. Med. 24 (1998) 913-923
320. Ravizza R., Cereda E., Monti E., and Gariboldi M. The piperidine nitroxide Tempol potentiates the cytotoxic effects of temozolomide in human glioblastoma cells. Int. J. Oncol. 25 (2004) 1817-1822
321. Schubert R., Erker L., Barlow C., Yakushiji H., Larson D., Russo A., Mitchell J., and Wynshaw-Boris A. Cancer chemoprevention by the antioxidant tempol in Atm-deficient mice. Hum. Mol. Genet. 13 (2004) 1793-1802
322. Zhang Q., Eaton L., Snyder E., Houghtaling S., Mitchell J., Finegold M., Van Waes C., and Grompe M. Tempol protects against oxidative damage and delays epithelial tumor onset in Fanconi anemia mice. Cancer Res. 68 (2008) 1601-1608
323. Glover C., Rabow A., Isgor Y., Shoemaker R., and Covell D. Data mining of NCI's anticancer screening database reveals mitochondrial complex I inhibitors cytotoxic to leukemia cell lines. Biochem. Pharmacol. 73 (2007) 331-340
324. Grimberg H., Levin G., Shirvan A., Cohen A., Yogev-Falach M., Reshef A., and Ziv I. Monitoring of tumor response to chemotherapy in vivo by a novel small-molecule detector of apoptosis. Apoptosis 14 (2009) 257-267
325. Zhao Y., Neuzil J., and Wu K. Vitamin E analogues as mitochondria-targeting compounds: from the bench to the bedside?. Mol. Nutr. Food Res. 53 (2009) 129-139
326. o site of the mitochondrial complex III is required for the transduction of hypoxic signaling via reactive oxygen species production. J. Cell Biol. 177 (2007) 1029-1036
327. Xiao D., Vogel V., and Singh S. Benzyl isothiocyanate-induced apoptosis in human breast cancer cells is initiated by reactive oxygen species and regulated by Bax and Bak. Mol. Cancer Ther. 5 (2006) 2931-2945
328. Zhang R., Loganathan S., Humphreys I., and Srivastava S. Benzyl isothiocyanate-induced DNA damage causes G2/M cell cycle arrest and apoptosis in human pancreatic cancer cells. J. Nutr. 136 (2006) 2728-2734
329. Kalkunte S., Swamy N., Dizon D., and Brard L. Benzyl isothiocyanate (BITC) induces apoptosis in ovarian cancer cells in vitro. J. Exp. Ther. Oncol. 5 (2006) 287-300
330. Conradt P., Dittmar K., Schliephacke H., and Trowitzsch-Kienast W. Myxothiazol: a reversible blocker of the cell cycle. J. Antibiot. (Tokyo). 42 (1989) 1158-1162
331. Han Y., Kim S., Kim S., Park W., and Antimycin A. as a mitochondrial electron transport inhibitor prevents the growth of human lung cancer A549 cells. Oncol. Rep. 20 (2008) 689-693
332. Han Y., and Park W. Growth inhibition in antimycin A treated-lung cancer Calu-6 cells via inducing a G1 phase arrest and apoptosis. Lung Cancer (2008)
333. Suter M., Remé C., Grimm C., Wenzel A., Jäättela M., Esser P., Kociok N., Leist M., and Richter C. Age-related macular degeneration. The lipofusion component N-retinyl-N-retinylidene ethanolamine detaches proapoptotic proteins from mitochondria and induces apoptosis in mammalian retinal pigment epithelial cells. J. Biol. Chem. 275 (2000) 39625-39630
334. Okamaoto M., Ohsato T., Nakada K., Isobe K., Spelbrink J., Hayashi J., Hamasaki N., and Kang D. Ditercalinium chloride, a pro-anticancer drug, intimately associates with mammalian mitochondrial DNA and inhibits its replication. Curr. Genet. 43 (2003) 364-370
335. Segal-Bendirdjian E., Coulaud D., Roques B., and Le Pecq J. Selective loss of mitochondrial DNA after treatment of cells with ditercalinium (NSC 335153), an antitumor bis-intercalating agent. Cancer Res. 48 (1988) 4982-4992
336. Sun X., Wong J., Song K., Hu J., Garlid K., and Chen L. AA1, a newly synthesized monovalent lipophilic cation, expresses potent in vivo antitumor activity. Cancer Res. 54 (1994) 1465-1471
337. Salomon A., Voehringer D., Herzenberg L., and Khosla C. Apoptolidin, a selective cytotoxic agent, is an inhibitor of F0F1-ATPase. Chem. Biol. 8 (2001) 71-80
338. Athar M., Back J., Tang X., Kim K., Kopelovich L., Bickers D., and Kim A. Resveratrol: a review of preclinical studies for human cancer prevention. Toxicol. Appl. Pharmacol. 224 (2007) 274-283
339. Wise D.R., DeBerardinis R.J., Mancuso A., Sayed N., Zhang X.Y., Pfeiffer H.K., Nissim I., Daikhin E., Yudkoff M., McMahon S.B., and Thompson C.B. Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction. Proc. Natl. Acad. Sci. U. S. A. 105 (2008) 18782-18787